HCC

FOG-001 in Locally Advanced or Metastatic Solid Tumors

IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Optimizing Y90 Therapy for Radiation Lobectomy

Cabozantinib in Hepatocellular Carcinoma

Pembrolizumab in Hepatocellular Carcinoma

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

SBRT in HCC With Oligoprogression on First-line Immunotherapy

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

REGULUS: MRI-guided Adaptive SABR for Liver Cancers

Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma

TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension

Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular

Preliminary Evaluation of Clinical Application of SPECT Imaging Targeting GPC3

Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

ICIs With and Without MWA in Advanced Hepatocellular Carcinoma

TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma

A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC